| __timestamp | GSK plc | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3450000000 | 79696000 |
| Thursday, January 1, 2015 | 3560000000 | 93236000 |
| Friday, January 1, 2016 | 3628000000 | 150842000 |
| Sunday, January 1, 2017 | 4476000000 | 150643000 |
| Monday, January 1, 2018 | 3893000000 | 150252000 |
| Tuesday, January 1, 2019 | 4568000000 | 140804000 |
| Wednesday, January 1, 2020 | 5098000000 | 34236000 |
| Friday, January 1, 2021 | 5278000000 | 35672000 |
| Saturday, January 1, 2022 | 5488000000 | 66607000 |
| Sunday, January 1, 2023 | 6223000000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Data in motion
In the ever-evolving pharmaceutical landscape, investment in research and development (R&D) is a key indicator of a company's commitment to innovation. Over the past decade, GSK plc has consistently outpaced Halozyme Therapeutics, Inc. in R&D spending. From 2014 to 2023, GSK's R&D expenses surged by approximately 80%, peaking at $6.2 billion in 2023. In contrast, Halozyme's investment remained relatively modest, with a peak of $150 million in 2016, and a notable dip to $34 million in 2020. This disparity highlights GSK's robust strategy to maintain its competitive edge through innovation. As the pharmaceutical industry faces increasing challenges, such as regulatory changes and market competition, GSK's substantial R&D investment underscores its commitment to pioneering new treatments and therapies. Meanwhile, Halozyme's more conservative approach may reflect a strategic focus on niche markets or partnerships.
R&D Spending Showdown: Merck & Co., Inc. vs GSK plc
Research and Development Investment: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
GSK plc or Biogen Inc.: Who Invests More in Innovation?
Research and Development Investment: GSK plc vs Opthea Limited
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Alpine Immune Sciences, Inc.
R&D Insights: How GSK plc and Protagonist Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: GSK plc vs Vericel Corporation
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Halozyme Therapeutics, Inc.
Research and Development Investment: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and MorphoSys AG
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Viridian Therapeutics, Inc.